292 related articles for article (PubMed ID: 17488374)
21. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
Chambers HF
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():17-22. PubMed ID: 16524424
[TBL] [Abstract][Full Text] [Related]
22. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
23. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
24. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Vidaillac C; Rybak MJ
Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
[TBL] [Abstract][Full Text] [Related]
25. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
26. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
27. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
Biek D; Critchley IA; Riccobene TA; Thye DA
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
[TBL] [Abstract][Full Text] [Related]
28. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
30. MRSA--the tip of the iceberg.
Appelbaum PC
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
[TBL] [Abstract][Full Text] [Related]
31. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of action and antimicrobial activity of ceftobiprole.
Morosini MI; Díez-Aguilar M; Cantón R
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):3-10. PubMed ID: 31364335
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008).
Ishii Y; Ueda C; Kouyama Y; Tateda K; Yamaguchi K
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):443-8. PubMed ID: 21396543
[TBL] [Abstract][Full Text] [Related]
34. Combating resistance in a challenging, changing environment.
Goldstein FW
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():2-6. PubMed ID: 17488370
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
[TBL] [Abstract][Full Text] [Related]
37. The bacteria fight back.
Taubes G
Science; 2008 Jul; 321(5887):356-61. PubMed ID: 18635788
[No Abstract] [Full Text] [Related]
38. Can beta-lactams be re-engineered to beat MRSA?
Livermore DM
Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():11-6. PubMed ID: 16524423
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Lee SY; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
[TBL] [Abstract][Full Text] [Related]
40. [Review of oral cephalosporins. Basis for a rational choice].
Forti IN
Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
